Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab lead-in versus concurrent nivolumab with paclitaxel/carboplatin as neoadjuvant therapy in early stage triple negative breast cancer
2019-003465-18Phase 2Active
- Sponsor
- Breast Cancer Trials
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of nivolumab in breast cancer (2 arms), sponsored by Breast Cancer Trials. Primary endpoint: Pathological complete response (pCR breast and nodes). Started Oct 2021; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-003465-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003465-18.